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Abstract Using the baculovirus expression system the g ne products of human tapl and tap2 were over-expressed as wild-type as well oligohis- 
tidine fusion proteins in Spodopterafrugiperda (Sf9) insect cells, Both gene products were co-expressed within the same cells and were found nriched 
in microsomal membranes. Immunoprecipitation and immobilized metal affinity chromatography revealed complex formation between TAP1 and 
TAP2. The expressed TAP complex was shown to be functional by peptide translocation into microsomes f Sf9 cells. Peptide transport strictly 
requires TAP1 and TAP2 as well as ATE For the first time the functional expression ofthe human TAP complex in insect cells has been demonstrated, 
indicating that additional cofactors f a highly developed immune system are not ess ntial for peptide transport across microsomal membranes. 
Key words: ABC transporter; Membrane protein; Traffic ATPase; Antigen presentation; Peptide transport; Baculovirus; Insect cell 
1. Introduction 
Antigen presentation by major histocompatibility complex 
(MHC) class I molecules requires limited proteolysis of intra- 
cellular antigens, translocation of the derived peptides into the 
lumen of the endoplasmic reticulum (ER), and association with 
the assembling MHC class I molecules. Subsequently, class 
I-peptide complexes are transported to the cell surface, where 
they can be recognized by the appropriate CD8 ÷ T lymphocytes 
(for review see [1,2]). 
Two genes, named tap1 and tap2, which are essential for 
correct MHC class I antigen presentation, have been identified 
in the MHC class 11 gene region and sequenced for human [3~], 
mouse [7,8] and rat [9,10]. Comparison of amino acid sequences 
revealed that TAP proteins exhibit a high degree of homology 
with a superfamily of proteins known as the ABC transporters 
[11], possessing two predicted ATP binding cassettes (ABC) 
and two stretches of 6-8 membrane-spanning regions [12]. 
TAP1 and TAP2 are thought o form a heterodimer [13,14] 
located in the membrane of the ER and cis-Golgi [15]. Other 
members of the family include the multidrug resistance 
P-glycoprotein (MDR) [16], the cystic fibrosis transmembrane 
conductance regulator (CFTR) [17], the oligopeptide trans- 
porter of Salmonella typhimurium [18] and the yeast protein 
Ste6 [19,20]. 
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Two lines of evidence support the idea that the TAPI/2 
complex translocates antigenic peptides into the lumen of the 
ER for association with MHC class I molecules: (i) restoration 
of correct antigen presentation i defective mutant cell lines 
transfected with the corresponding human [21], mouse [22] or 
rat [23] tap genes, and (ii) peptide translocation assays using 
permeabilized cells [24,25] or microsomes prepared from mam- 
malian cell lines [26]. In general, these assays take advantage 
of core glycosylation or binding of translocated radiolabelled 
peptides to MHC class I molecules in the ER or microsomal 
lumen, respectively, preventing rapid export out of the ER. 
Sequence specificity, length selectivity of the peptides, as well 
as ATP-dependence of the translocation [27-30] were investi- 
gated in these assays. Furthermore, nucleotide binding studies 
to the hydrophilic, C-terminal domains of the transporter indi- 
cate a direct interaction and regulatory function f ATP [31]. 
For understanding the molecular architecture and further char- 
acterization of the function of the complex, possibly in an in 
vitro translocation assay with purified reconstituted TAPI/2 
complex, large amounts of active protein are required. 
The baculovirus expression system is well suited for the over- 
expression of transmembrane proteins; a wide array of them 
have been successfully expressed in a functionally active state, 
including the Na+/H ÷ [32] and the Na+/Ca 2÷ [33] antiporter, the 
Na÷/glucose co-transporter [34], and the two subunit complex 
H+/K+-ATPase [35]. Other examples are the ABC transporters 
multidrug resistance P-glycoprotein (MDR) [36,37] and the cys- 
tic fibrosis transmembrane conductance regulator (CFTR) 
[38]. 
In this study, we report on the expression and formation of 
a functionally active TAP1/2 complex in Sf9 cells using the 
baculovirus expression system. Co-expression of the proteins 
was confirmed by immunoblotting, precipitation and fluores- 
cence. Strategies for isolation of the complex were developed, 
demonstrating that the TAP complex has the stoichiometry 
TAPI/TAP2 of 1:1 when solubilized using the appropriate de- 
tergent. Functionality of the complex was shown to require 
both components of the complex and to be ATP-dependent. 
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2. Materials and methods 
2.1. DNA constructs 
Using PCR, human tapl and tap2 cDNAs (kind gifts from Dr. J. 
Trowsdale [3]) were amplified as wild-type genes and in the case of tap1 
the codons for 6 histidine residues were inserted at the 3' terminus. 
Subsequently, the PCR products were cloned as BglII-XbaI fragments 
into the baculovirus transfer vector pVLI392 (Invitrogen, USA). Alter- 
natively, the cDNAs of tapl and tap2 were inserted into the baculovirus 
co-expression vector pAcUW51 (Pharmingen, USA) resulting in 
pAcUW51/TAP1/TAP2 and pAcUW51/TAPI~ x His/TAP2. In par- 
allel, the baculovirus vector pVL1393 harboring the cDNAs of tapl and 
tap2 were used to generate recombinant baculoviruses [39]. The con- 
structs were evaluated by restriction analysis and their correct se- 
quences determined by sequencing ofthe inserts by the dideoxynucleo- 
tide method (USB Sequenase kit, USA) [40]. 
2.2. Cell culture and protein expression 
Recombinant baculoviruses carrying the human tap genes were gen- 
erated by co-transfection f Sf9 (Spodoptera f ugiperda) cells with the 
recombinant transfer vectors together with linearized baculovirus 
Baculogold DNA (Pharmingen, USA) using the lipofection reagent 
DOTAP (Boehringer, Germany). Infection of Sf9 cells grown as a 
monolayer was routinely performed with a multiplicity of infection 
(m.o.i.) of about 3-5; culture conditions followed standard procedures 
[42]. 
Anti-TAPI monoclonal (148.3) or polyclonal ntibody raised against 
a C-terminal peptide of TAP1 0Vesse and Tamp~, in prep.) and anti- 
TAP2 mAbs (435.3 and 429.3) raised against a baculovirus-expressed 
280 aa C-terminal fragment of TAP2 [39] were used for immunoblotting 
and fluorescence. Immunoprecipitation experiments were carried out 
by incubating mAb 148.3 with extracts of St9 cells, followed byprecip- 
itation of the complex with protein A-Sepharose (Sigma, USA). Im- 
munofluorescence was performed according to [42] using fluorescein 
(FITC)- and rhodamine (TRITC)-coupled goat anti-mouse and anti- 
rabbit antibodies (Sigma, USA). 
2.3. Purification f the TAP complex 
Purification of the TAP complex containing the TAPI-6 x His fusion 
protein was performed by immobilized metal affinity chromatography 
(IMAC). 10 7 Sf9 cells (60 h p.i.) were lysed in 2 ml 150 mM Na2HPO4, 
pH 8.0 containing 1.5% dodecyl-fl-D-maltoside (DM; Sigma, USA). 
After centrifugation (10 min, 12,000 x g at 4*C) the solubilized proteins 
were applied to a Ni-IDA column (Pharmacia, Germany). The column 
was pre-equilibrated in buffer A (1 mM DM, 150 mM Na2HPO4, pH 
8.0) and proteins were eluted using a gradient of 0-200 mM imidazole 
in buffer A. The TAP-containing fraction was analyzed by size-exclu- 
sion chromatography using a Superose 6 column (Pharmacia, Ger- 
many) with buffer A as running buffer at a flow rate of 0.3 ml/min. 
Elution of proteins was followed by absorbance (OD2s0) or tryptophan 
fluorescence detection (2ex/Aem = 280/350nm). Fractions of 1 ml were 
analyzed by immunoblotting with TAP1- and TAP2-specific anti- 
bodies. 
2.4. Preparation of microsomes 
For preparation ofmicrosomes from Sf9 cells about 108 cellsdml were 
lysed by repeated rawing through a 26 gauge needle in cavitation 
buffer (250 mM sucrose, 25m M KOAc, 5 mM MgOAe, 0.5 mM 
CaOAc, 50 mM Tris, pH 7.4) with proteinase inhibitor mix. After 
centrifugation for 5 rain at 1000 rpm (4°C), the supernatant was diluted 
6.4-fold with 2.5 M sucrose olution in gradient buffer (150 mM KOAc, 
5 mM MgOAc, 50 mM Tris, pH 7.4) and subsequently overlaid with 
2.0 M sucrose solution and 1.3 M sucrose solution (both in gradient 
buffer). The step gradient was centrifuged overnight (4°C, 85,000 x g)
and the microsomes accumulated at the interface of the 2.0 and 1.3 M 
sucrose solution were washed once with PBS, 1 mM DTT and centri- 
fuged for 2 h (4°C, 190,000 ×g). After resuspending in PBS, 1 mM 
DTT, the microsomes were snap-frozen i liquid nitrogen and stored 
at -80°C. 
2.5. Peptide translocation assay 
The peptide R-10-T (RYWANATRST) was synthesized by the solid- 
phase technique and purified by reverse-phase chromatography. Its
identity was verified by mass pectrometry. Iodination of 15/tg R-10-T 
with 1 mCi Na125I (Amersham, USA) was performed using free chlo- 
ramin T [43]. Iodinated peptide (R-10-T*) was eparated from free 
Na 1251 by gel-filtration through a Sephadex G 10(Pharmacia, Germany) 
column. The peptide translocation assay was performed according to 
[24,25]. Microsomes were incubated in 150/~1 of buffer T (PBS; 0.1% 
dialyzed BSA, 10 mM MgCI2, 1 mM DTT) with -50 ng (~40 pmol) of 
R-10-T* (~ 1.5 × 106 cpm) in the presence or absence of ATP, apyrase, 
A MP-PNP (all Sigma, USA) and a t 00-fold excess of unlabelled R-10-T 
for 10 min at 37°C. After one washing step, the microsomes were lysed 
by addition of 1 ml lysis buffer (1% NP-40, 150 mM NaCI, 5 mM 
MgCI2, 50 mM Tris-HCl, pH 7.5). After centrifugation (2500 x g, 
5 min, 4°C) the supernatant was incubated for 2 h with 100/~l of 
Concanavalin A-Sepharose (Sigma, USA) at 4°C, washed two times, 
and bound peptide was eluted with 1 ml 200 mM ~-methylmannoside 
(Sigma, USA) in lysis buffer (60 min at room temperature) and quanti- 
fied by 7-counting. 
3. Results and discussion 
3.1. Expression and localization of TAP1 and TAP2 
Human TAP1 and TAP2 were expressed in St9 insect cells 
using the baculovirus expression system. After PCR amplifica- 
tion of the cDNAs, human tap1 and tap2 were inserted into the 
transfer vectors pVL1392 and pAcUW51. In order to establish 
a mild procedure for protein purification, we generated a fusion 
construct coding for TAP 1 with a C-terminal stretch of 6 histid- 
ine residues (TAPI~5 x His). All constructs were confirmed by 
DNA sequencing. 
The time-dependent expression of the TAP proteins in Sf9 
cells infected with recombinant baculovirus containing the 
genes for TAP I~ x His (rBV-TAP1-6 x His) and TAP2 (rBV- 
TAP2) is shown in Fig. 1. Total cellular proteins were separated 
by SDS-PAGE, and analyzed by immunoblotting with TAPI-  
and TAP2-specific monoclonal antibodies (Fig. la,b). TAP1- 
6 x His and TAP2 were detected at a molecular weight of about 
75 kDa. Comparison of the recombinant proteins of all our 
constructs with cell extracts of different human cell lines re- 
vealed identity of the molecular weights of the wild-type TAPI/  
2 proteins (71/75 kDa). Due to the additional fusion tag, TAP 1- 
6 x His runs at a slightly higher molecular weight; thus, TAP1- 
6 x His could not be separated from TAP2. Cell extracts from 
non-infected or wild-type baculovirus (BVwt)-infected Sf9 cells 
did not express TAP proteins (Fig. lc). Insect cells infected with 
rBV-TAP1 and rBV-TAP2 were treated with tunicamycin and 
total cellular proteins were analyzed by SDS-PAGE. No shift 
in molecular weights of the TAP proteins was observed, indi- 
cating that TAP1 and TAP2 are not glycosylated (data not 
shown). For all constructs, the protein expression is under the 
control of a strong, late viral promotor (ph or pl0) correlating 
with an expression maximum between 48 and 72 h after infec- 
tion. After 72 h degradation products are visible. Therefore, 
cells were routinely harvested 60 h p.i. 
Immunofluorescence microscopy was performed with in- 
fected Sf9 cells (rBV-TAPI/rBV-TAP2 and BVwt) using 
TAPl-specific pAbs or mAbs and TAP2-specific mAbs. In 
TAP-expressing cells a heterogeneous fluorescence pattern cen- 
tered around the nucleus indicates that TAP1 and TAP2 are 
localized in cytoplasmic compartments, most probably in the 
ER (Fig. 2). TAP1 and TAP2 could not be detected in the 
plasma membrane or in the nucleus. By co-labelling with 
TAPl-specific polyclonal and TAP2-specific monoclonal anti- 
bodies both proteins could be localized within the same cell 
although not always in equal amounts. This reflects the fact 
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Fig. 1. Time-dependent co-expression of TAP1 and TAP2 in Sf9 ceils. Immunoblot f SDS-PAGE (8-18%) of Sf9 insect ceils infected with recombinant 
baculovirus containing the g nes of TAPI~ x His and TAP2. Total cellular proteins of-5 x 105 cells harvested 12h (lane 1), 36 h (lane 2), 48 h (lane 
3), 60 h (lane 4), 72 h (lane 5) and 94 h (lane 6) after infection were treated with the TAP1 specific mAb 148.3 (a) and the TAP2 specific mAb 435.3 
(b). Lanes 7 and 8 show total cellular proteins of non-infected and wild-type baculovirus infected Sf9 ceils, respectively, harvested 72 h after infection 
and treated with both monoclonal antibodies (c). 
that the cells shown in Fig. 2 are infected with rBV-TAP1 and 
rBV-TAP2 but it may be that not every single cell is co-infected 
at the same time. Comparative immunoblots of total cell ex- 
tracts, membrane fractions and subcellular organelles reveal 
that TAP proteins are found in membrane fractions enriched 
in the microsomes corresponding to the rough and smooth ER 
(data not shown). These results are in agreement with the ob- 
served localization of TAP in mammalian cells by immunogold 
labelling [15]. 
3.2. Complex formation 
To address the question of whether TAPI and TAP2 over- 
expressed in insect cells associate with each other, a number of 
detergents were tested for effective solubilization of the TAP 
proteins. Dodecyl-fl-D-maltoside proved to be very suitable for 
mild, but effective, solubilization of the TAP complex. Subse- 
quent immunoprecipitation with our TAPl-specific mAb dem- 
onstrated that both TAP proteins are still associated under 
these conditions, since TAP2 co-precipitates together with 
TAP1 (data not shown). For comparison with affinity chroma- 
tography using TAP-specific antibodies, which usually includes 
rather harsh elution conditions, a method for mild isolation and 
purification of the TAP complex was developed. Solubilized 
proteins of Sf9 cells infected with rBV-TAP1-6 x HisFFAP2 
were separated by metal chelate affinity chromatography 
(Fig. 3). Weakly bound proteins were removed by washing 
Fig. 2. Localization of TAP1 and TAP2 in Sf9 ceils. Sf9 cells infected with rBV-TAPI/rBV-TAP2 (a-c) and BVwt (dO were visualized by 
immunofluorescence of fluorescein (a,d) or rhodamine (b,e) and phase contrast (c,0 48 h p.i. Cells were co-labelled with the pAb specific against 
TAP1 (1:50) and mAb 429.3 specific against TAP2 (1:25) followed by incubation with a goat anti-rabbit fluorescein-coupled antibody (F1TC-IgG) 
and goat anti-mouse rhodamine-coupled antibody (TRITC-IgG). 
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Fig. 3. Purification and complex formation of TAP1 and TAP2. Sf9 
cells expressing the TAP complex containing TAPI~ x His and TAP2 
were lysed 60 h p.i. and solubilized proteins were applied onto a Ni-IDA 
Sepharose column. (a) Chromatogram of the Ni-IDA column run. 
Proteins were eluted with buffer A containing 10 m M imidazole (W l), 
40 mM imidazole (W2) and 200 mM imidazole (E). The elution was 
detected by tryptophan fluorescence (/1.ex/g~m = 280/350 nm). (b) Pro- 
teins in total cell extract (S), flow through (F), wash 1 (Wl), wash 2 
(W2) and elution (E) were separated by SDS-PAGE (8-18%). Coomas- 
sic staining (b) and immunobiotting with the TAP 1-specific mAb 148.3 
(c) and the TAP2-specific mAb 435.3 (d) are shown. Lane M contains 
marker proteins (92.5, 67.0, 45.0 and 29.0 kDa). 
steps with 10 mM and 40 mM imidazole, respectively. Specifi- 
cally bound proteins were eluted with 200 mM imidazole 
(Fig. 3a). SDS-PAGE confirmed that this protein peak con- 
sisted of purified protein with a molecular weight of about 75 
kDa (Fig. 3b). By immunoblotting this band was identified to 
be a mixture of both TAP proteins (Fig. 3c,d). To answer the 
question of whether the TAP complex is a heterodimer or 
multimer, the IMAC-purified TAP proteins were analyzed by 
size-exclusion chromatography. Under the solubilization con- 
ditions used for purification, the exclusion volume of the TAP 
complex corresponds to a molecular weight of about 200 + 50 
kDa. Assuming that the molecular weight of an average deter- 
gent micelle of DM is about 50 kDa, the TAP1/2 complex has 
the stoichiometry of 1:1 (150 kDa) under these solubilization 
conditions. 
3.3. TAP- and ATP-dependent peptide translocation 
To investigate whether the expressed TAP proteins are func- 
tional, peptide translocation assays were carried out using mi- 
crosomes prepared from infected insect cells (60 h p.i.). As a 
reporter peptide we used R-10-T* which bears an N-glycosyla- 
tion sequence. Assuming that glycosylation targeting in insect 
and mammalian cells is comparable, transported peptides 
should be glycosylated in microsomes and subsequently recov- 
erable by specific binding to Concanavalin A (Con A)-Sepha- 
rose. Our results demonstrate that microsomes containing 
TAP1 and TAP2 are active in ATP-dependent peptide accumu- 
lation (Fig. 4). Peptide transport into microsomes strictly re- 
quires expression of both proteins, since microsomes from Sf9 
cells infected only with rBV-TAP1 (Fig. 4), rBV-TAP2 or BVwt 
(data not shown) do not accumulate labelled peptides. TAP- 
dependent peptide translocation is an active transport process 
requiring the hydrolysis of ATP, which is shown by a 35-fold 
increase in R-10-T* (28,600 cpm, 1.5% of the total radioactiv- 
ity) eluted from Con A-Sepharose in the presence of 10 mM 
ATP. Blocking of the ATP-binding domain by incubation with 
the non-hydrolyzable ATP-analogue AMP-PNP resulted in no 
recovery of glycosylated peptide. Translocation of radioactive 
peptides was completely inhibited by competition with a 
100-fold excess of unlabelled peptide (R-10-T) in the presence 
of 10 mM ATP. Assays with microsomes containing TAP com- 
plexes tagged with an oligohistidine s quence revealed the same 
results. 
In this paper we demonstrate for the first time that peptide 
translocation i to the ER of insect cells infected with recombi- 
nant baculovirus containing human tap1 and tap2 could be 
proven, and that other cofactors of a highly developed cellular 
immune system are not essential. Over-expressed TAP proteins 
assemble to form a stable complex highly enriched in the ER 
membrane. Using insect cell microsomes over-expressing TAP 
proteins we have also demonstrated direct binding of peptide 
substrates to the TAP complex, providing additional evidence 
for the functional state of insect cell-expressed TAP proteins 
[39]. Therefore, microsomal embranes of infected Sf9 cells are 
highly suitable for peptide binding and translocation assays as 
+ apyrase 
+ ATP 
+ ATR 
+ R-10-T 
+ AMP-PNP 
I 
' " ' ' I " ' ' ' I " ' ' ' I . . . .  I . . . .  I ' ' ' ' 
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[]  TAP 1 
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Con A eluted peptide [ x 103 cprn] 
Fig. 4. Peptide translocation into microsomes. Microsomes of infected 
Sf9 cells containing both TAP proteins (TAPI/2) or only TAPI were 
incubated with radioactive peptide (R-10-T*) in the presence or absence 
of apyrase (20 U/ml), ATP (10 mM), AMP-PNP (10 mM) and a 100- 
fold excess of non-labelled R-10-T for 10 min at 37°C. The radioactivity 
of specifically eluted R-10-T* from the Con A-Sepharose r presents he 
amount of transported and glycosylated peptide. 
T.H. Meyer et al./FEBS Letters 351 (1994) 443-447 447 
well as for isolation of the transporter complex in large quanti- 
ties. Strategies were developed for purification of the solubil- 
ized complex. From the translocation assays described, strong, 
although only indirect, evidence for the essential function of the 
peptide transporter for antigen processing was found. Isolation 
and functional reconstitution f the TAP complex into artificial 
membranes i a promising approach to study the mechanism 
of substrate recognition and transport as well as the structure 
of the ABC transporter. 
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